Company intelligence / Profile preview

Ysotope Theranostics

Barcelona, Catalonia, Spainysotope.com ↗

Ownership: Private
Development stage: Other

Overview

Ysotope Theranostics develops advanced PET radiotracers to enable non-invasive molecular imaging, with a focus on tracking CAR T cells and targeting leukemic stem cells. Their lead program aims to validate a novel diagnostic agent for neuroblastoma. The company leverages co-development partnerships and licenses its IP, with initial proof-of-concept studies underway. No clinical trial results have been published yet.

Therapeutic areas: HematologyOncology
Modalities: RadiopharmaceuticalPET radiotracer
Industry: Biotech

Partnerships

Vall d’Hebron Institut de Recerca (VHIR) spin-off network

Beyond the preview

Go deeper on Ysotope Theranostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ysotope Theranostics.

Explore the full profile